Cognitive impairment has been reported in some chronic users of psychostimulants, raising the possibility that long-term drug exposure might damage brain neuronal systems, including the cholinergic system, which are responsible for normal cognition. We measured the activity of choline acetyltransferase (ChAT), the marker enzyme for cholinergic neurones, in autopsied brain of chronic users of cocaine, methamphetamine, and, for comparison, heroin. As compared with the controls, mean ChAT levels were normal in all cortical and subcortical brain areas examined. However, the two of 12 methamphetamine users, who had the highest brain/blood drug levels at autopsy, had a severe (up to 94%) depletion of ChAT activity in cerebral cortex, striatum, and thalamus. Based on the subjects examined in the present study, our neurochemical data suggest that brain cholinergic neurone damage is unlikely to be a typical feature of chronic use of cocaine, methamphetamine, or heroin, but that exposure to very high doses of methamphetamine could impair, at least acutely, cognitive function requiring a normal nucleus basalis cholinergic neuronal system. Reduced brain ChAT might be explained in part by a hyperthermia-related mechanism as low ChAT levels have also been observed in brain of some patients with neuroleptic drug-associated hyperthermia. Studies of cognitive and brain cholinergic status in high dose users of MA are warranted.
Introduction
Cognitive impairment can be associated with long-term use of the psychostimulant drug cocaine. In this regard, typically modest neuropsychological deficits on tests sensitive to damage to executive system functioning, verbal learning, and memory have been reported in some chronic cocaine users. [1] [2] [3] [4] [5] [6] [7] [8] However, the structural cause of the deficits (eg, drug toxicity to specific brain areas, global microvascular damage, etc) has not yet been determined. Furthermore, in the absence of prospective studies, it is not possible to determine whether such neuropsychological test deficits might have preceded use of the drug. 9 In the case of the psychostimulant methamphetamine, although acute high dose exposure to this psychostimulant can produce impaired cognitive status in the human, 10 no infor-mation appears to be available on the influence of longterm exposure of this drug on cognitive status. Much experimental animal and clinical data suggest that brain cholinergic neurones originating in the nucleus basalis brain area and terminating in the cerebral cortex subserve aspects of executive system function, especially attentional processes, [11] [12] [13] which have been reported to be affected in some psychostimulant users. 4, 6, 7 As a first step in determining whether longterm exposure to psychostimulants might damage the nucleus basalis cholinergic system, and thereby contribute to such cognitive deficits, we measured the activity of choline acetyltransferase (ChAT), the cholinergic marker synthetic enzyme, in autopsied cerebral cortex, as well as in other brain areas, of chronic human users of cocaine, amphetamine, and, for comparison, in brain of a group of users of heroin. We report that brain ChAT levels are normal in all three drug abuse groups with the exception of those users of methamphetamine who had been exposed to very high doses of the drug.
Patients and methods
Postmortem brain material from a total of 12 controls, 11 users of cocaine, 12 users of methamphetamine, and nine users of heroin was obtained from medical examiner offices in the US and Canada. As shown in Table 1 , the mean ages and postmortem time (interval between death and freezing of the brain) between the control and drug abuse groups did not differ significantly (one way analysis of variance (ANOVA); P Ͼ 0.05). At autopsy, one half-brain was fixed in formalin fixative whereas the other half was immediately frozen at −80°C until biochemical analysis. Samples of cardiac blood were obtained from all of the drug users and from the control subjects for drug screening. Scalp hair samples for drug analyses could be obtained from nine of the 12 control subjects, seven of the 11 cocaine users, seven of the 12 methamphetamine users, and eight of the nine heroin users. Levels of drugs of abuse in blood and other bodily fluids were measured by the local medical examiner whereas drug analyses in brain and hair samples were conducted at the Armed Forces Institute of Pathology (KK; Washington, DC, USA).
Control subjects
Autopsied brain was obtained from 12 neurologically normal subjects who died from a variety of causes (gunshot wound to chest (2), chest trauma (2), cardiovascular disease (5), perforated vena cava (1), leukemia (1), and drowning (1)). All subjects tested negative for drugs of abuse in blood, autopsied brain, and, in the seven cases for which hair was available, sequential hair samples.
Drug users
The subjects for the cocaine, methamphetamine, and heroin groups were selected from a large group of potential cases who met the following criteria: (1) presence of cocaine and/or metabolite benzoylecgonine, or methamphetamine, or heroin metabolites (6-acetylmorphine, morphine, or morphine glucuronide), on toxicology screens in blood or urine, autopsied brain (see below), and, if available, scalp hair; (2) absence of other drugs of abuse in bodily fluids with the exception of ethanol; (3) evidence from the case records of use of the primary drug for at least 1 year prior to death; and (4) absence of neurological illness or, at autopsy, brain pathology unrelated to use of the drug. Most of the potential subjects were rejected because of a known history of significant polydrug abuse or the presence of other drugs of abuse in blood or brain at autopsy. Alcohol was known to have been used by eight of the 11 cocaine users and all 12 of the heroin users as evidenced by review of the case records and by presence in bodily fluids or brain of ethanol or cocaethylene (the transesterification product of cocaine and ethanol). Ethanol was not detected in bodily fluids of any of the methamphetamine users. With the exception of one cocaine user in which cocaine was detected in urine but not blood, all of the other users of cocaine, methamphetamine, and heroin, tested positive for the drug of abuse in blood and brain, suggesting that each subject had used the drug during the 72 h preceding death. Clinical information was obtained by the medical examiners using a questionnaire format and through structured telephone interviews with the next of kin. No formal neuropsychological testing had been conducted on the drug users.
Clinical, toxicological, and pathological data, including suspected cause of death, have been previously published for the 11 cocaine users 14 and 12 users of methamphetamine. 15 For the heroin users the suspected causes of death were acute narcotic intoxication for 11 of the 12 heroin users and atherosclerotic cardiovascular disease with acute narcotic intoxication as a contributing factor in one subject. Brain neuropathological analyses of the heroin users disclosed no significant abnormalities with the exception of mild ventricular dilatation (n = 1) and mild diffuse gliosis in diencephalon and lower brain stem (n = 1).
Brain dissection for neurochemical analysis
Cerebral cortical subdivisions were excised using the Brodmann classification. Following dissection of the cerebral cortical subdivisions, approximately 2.5 mmthick coronal sections of the brain were taken beginning with the anterior tip of the head of the caudate nucleus to the tail of the caudate. Subcortical brain areas were dissected using the Atlas of Riley 16 and as previously described.
17,18
Neurochemical analyses ChAT activity in brain homogenates was determined by minor modifications of the radioenzymatic procedure of Fonnum and coworkers. 19 Activities of citrate synthase 20 and glyceraldehyde-3-phosphate dehydrogenase 21 in brain homogenates were determined by spectrophotometric procedures.
Measurement of drugs of abuse
Levels of cocaine and its metabolites benzoylecgonine, ecgonine methyl ester, norcocaine, and cocaethylene were determined by a gas chromatography/mass spectrometry (GC-MS) procedure as previously described. 14 Concentrations of methamphetamine and amphetamine were determined by GC-MS. 15 For the measurement of heroin metabolites, a GC-MS analysis was performed using a Varian 3400 gas chromatograph equipped with a Satum 3 ion-trap mass spectrometer as the detector. A 5% phenyl-methylpolysiloxane capillary column (Hewlett Packard, HP-5MS, 30 m × 0.25 mm, 0.25 m film thickness) was used for the chromatographic separation with helium gas flow of 1 ml min −1 (200°C). Tandem MS was performed by resonant excitation and monitoring of daughter ion spectra. Electron ionization was employed throughout and the following selected ions were monitored: m/z 324, 340, 356 for 6-acetylmorphine derivative, m/z 287, 401, 414 for morphine derivative, and m/z 237, 346, 358 for d 3 -codeine derivative. (9) Values (pmol per 10 min per g protein) represent mean ± S.E. No statistically significant differences were observed between control subjects and the drug users (one way analysis of variance; P Ͼ 0.05). Abbreviations: PM (postmortem time; interval between death and freezing of the brain); cerebral cortical areas 10 (frontal); 21 (temporal); 17 (occipital); 7b (parietal); Nacs (nucleus accumbens); NPM (medial pulvinar nucleus of the thalamus); NL (nucleus lateralis of the thalamus). Table 1 shows the activities of ChAT in autopsied brain of the drug users. As compared with the controls, mean ChAT activity was normal in all brain areas examined of the drug users (one way ANOVA; P Ͼ 0.05). Examination of the individual subject values (see Figure 1 
Results
Spearman rank correlations were performed to determine whether there might be a relationship between amount of drug taken recently and enzyme activity. As an index of recent drug use, brain levels of 'total' cocaine (cocaine plus metabolites benzoylecgonine, ecognine methyl ester, norcocaine, cocaethylene), methamphetamine (methamphetamine plus amphetamine) and heroin metabolites (6-acetylmorphine plus morphine plus morphine glucuronide) were calculated. For the cocaine and methamphetamine users, drug levels were determined in all brain areas with the exception of the nucleus accumbens, whereas in the heroin group, drug levels were determined only in the occipital cortex, the latter which provided values used for correlations for all brain areas in this group. Complete details of the brain regional distribution of the drugs of abuse will be reported elsewhere. No statistically significant correlations were observed between brain ChAT activities and drug levels in the cocaine and heroin groups. For the methamphamine users statistically significant negative correlations (−0.65 to −0.81; P Ͻ 0.05) were observed between brain ChAT activity and methamphetamine plus amphetamine levels in all of the brain areas examined with the exception of the frontal cortex (−0.13; P Ͼ 0.05). However, examination of the individual subject values revealed that the significant negative relationship between amount of methamphetamine exposure and ChAT activity was primarily due to the two cases (cases a and b) who had the highest brain and blood drug levels and very low ChAT activities (see Figure 2 for occipital cortex). After exclusion of these two cases from the correlational analysis a trend for a negative relationship between total methamphetamine levels and ChAT activity was observed in all brain areas examined (r = − 0.30 to −0.66), with the exception of the frontal cortex (r = 0.27), which was statistically significant for the caudate nucleus only (r = −0.66, P Ͻ 0.05).
To determine whether the enzyme reduction in the two methamphetamine users with low brain ChAT might be explained by a non-specific phenomenon, activities of two additional enzymes which are stable postmortem in human brain and unrelated to ChAT and to each other, glyceraldehyde 3-phosphate dehydrogenase and citrate synthase, were measured in the occipital cortex, a region of brain in which ChAT activity was severely depleted in both cases (case a: Table 2 , activity of both 'control' enzymes was within or close to the limits of the control range with the exception of citrate synthase activity in case a, in which activity of the enzyme was reduced by about 50% of the mean control value.
Discussion
The major finding of our investigation is that brain ChAT activity is generally normal in chronic users of psychostimulant drugs and in users of heroin with the exception of methamphetamine users who are exposed to very high doses of the drug.
A limitation of our study is the lack of detailed information on the actual amount of drug taken on a daily basis by each of the subjects. In this regard, although our forensic drug analysis of blood and brain provides a general assessment of the amount of drug taken recently (ie, within approximately 72 h), and that of sequential hair samples (for those cases in which hair was available) confirms that the subjects must have used the drug chronically, it was not possible to obtain retrospective data detailing the precise amounts of drug taken over the last years before death. It is possible that our neurochemical data may have been confounded somewhat by the use of other drugs of abuse during the years before death. In this regard, although blood drug analysis revealed that none of the users of methamphetamine had detectable levels of ethanol at autopsy, ethanol could be detected in all of the heroin users and in most of the users of cocaine.
To the extent that the subjects in our investigation are representative of typical, chronic, drug users, our neurochemical data suggest that substantial damage to the nucleus basalis cholinergic system, or to other brain cholinergic neurones neurochemically assessed in our investigation (eg, striatal cholinergic interneurones) is not a typical feature of chronic use of psychostimulants or heroin in the human. This is in contrast to the marked degeneration of brain nucleus basalis cholinergic neurones in the dementing illness of Alzheimer's disease, in which, in our laboratory, cerebral cortical (temporal/parietal) ChAT activities are typically decreased by about 50-60%. 20 Although mean brain ChAT activity was normal in all three groups of drug users, two subjects, both methamphetamine users, had severely reduced ChAT levels in most of the brain areas examined (see cases a, b; Figure 1) . The clinical and forensic characteristics of these two subjects are shown in Table 3 . As these individuals had received, at least recently, as inferred from brain and blood methamphetamine concentrations, the highest drug doses of all of the methamphetamine users examined (Figure 2 ), it seems reasonable to conclude that a brain ChAT depletion might be restricted to those methamphetamine users who are exposed only to very high doses of the drug. Limited forensic information is available on the blood levels of methamphetamine associated with fatalities due to methamphetamine intoxication, with the interpretation of the available data complicated by factors such as tolerance and postmortem diffusion of the drug. In our study, blood levels of the two subjects having very low brain ChAT levels (7 mg L −1 ; 12.5 mg L ). 22, 23 In principle, as ChAT is the marker enzyme for cholinergic neurones, low ChAT in cases a and b could be explained by an actual loss of cholinergic neurones resulting from chronic use of methamphetamine. However, although no quantitative morphometric studies were conducted, extensive qualitative microscopic neuropathological examination of the brain, including the nucleus basalis brain area of cases a and b disclosed no evidence of cell loss or gliosis. In addition, our observation that, in these two subjects, the brain ChAT depletion was generally near-total and regionally widespread makes the possibility of a neartotal loss of brain cholinergic neurones unlikely. More likely, the reduced brain enzyme levels in cases a and b is explained by the acute toxic effects of high dose methamphetamine on ChAT itself, an enzyme well recognized for its stability in postmortem human brain. 24 This does not appear to be a direct inhibitory effect of residual brain methamphetamine on ChAT activity determined in vitro, as concentrations of MA (0.4 mM) 20 times that of the brain methamphetamine concentration resulting from the residual brain methamphetamine of case b (the subject with the highest brain methamphetamine concentration) had no effect on ChAT activity in frontal cortical homogenates of control subjects (n = 3; data not shown). Although we could not obtain information on the clinical state of either subject immediately following the last taking of the drug, we speculate that both users probably developed methamphetamine-induced hyperthermia, as may occur following high doses of methamphetamine, 10 and that the ChAT enzyme had been inactivated, perhaps irreversibly, by the hyperthermia. This possibility is in fact supported by our previous observation of a regionally widespread brain ChAT depletion in several patients who died in severe hyper- thermia associated with neuroleptic drug use. 25 In this regard, our finding that the activities of the 'control' enzymes in cases a and b were normal to marginally reduced could also be explained by general hyperthermic damage, but with the ChAT enzyme being much more susceptible to this damage.
Our neurochemical data suggest that although a brain cholinergic deficit is unlikely to be a typical feature of use of psychostimulants or of heroin, a brain ChAT depletion could occur in methamphetamine users who overdose on the drug. Should the ChAT inactivation be explained by hyperthermic damage, it is conceivable that a ChAT depletion might also occur in some high dose users of cocaine, which, like methamphetamine, can produce hyperthermia in the human. 26 With respect to functional considerations, we suggest that, as the nucleus basalis cholinergic system subserves aspects of normal cognition, the altered, sometimes disabling, mental status observed following methamphetamine overdose 10 could be explained in part by decreased nucleus basalis cholinergic function. In vitro data suggest that the half-life for ChAT might be on the order of at least 2 days. 27, 28 This allows for the possibility that a cholinergic-related cognitive impairment following acute methamphetamine might, in some overdose cases, be relatively long-lasting (ie 3-4 days), and possibly warranting pharmacologic treatment with an acetylcholinesterase inhibitor.
Despite the increasing use of methamphetamine in North America, 29 surprisingly little information is available regarding either the acute or long-term neurologic or psychiatric effects of the drug in the human. Our postmortem brain data suggest that further efforts are needed to describe in large sample sizes the clinical phenomenology of human methamphetamine use and, ultimately, the changes in brain which might explain the neuropsychiatric changes.
